An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman

Trial Profile

An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Anastrozole (Primary) ; Letrozole
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms CARIATIDE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Oct 2010 One-year results presented at the 35th Congress of the European Society for Medical Oncology
    • 24 Mar 2010 Patient number changed to 2758 from 4000 as per abstract present at 7th European Breast Cancer Conference.
    • 24 Mar 2010 Trial design and baseline data presented in an abstract at the 7th European Breast Cancer Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top